Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.
Histologically confirmed first diagnosis of cHL
Advanced-stage disease: stage IIB with large mediastinal mass and/or extranodal lesions or stage III or IV
No previous treatment for HL with the exception of steroid prephase
Confirmed HIV infection with CD4 counts ≥ 150/μL at registration or > 250/μL at any time within 8 months prior to HL diagnosis
Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment
Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
Multi-drug resistant HIV infection or concurrent AIDS-defining conditions
Pregnancy or breastfeeding